Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Endonovo Therapeutics Inc's Business Segments
Endonovo Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Endonovo Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Direct Sales Medical Care Providers Gross0%
- Royalty and Licensing Net0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Direct Sales Medical Care Providers Gross | $ 0 | - |
| Royalty and Licensing Net | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Endonovo Therapeutics Inc
Endonovo Therapeutics Inc, founded in 2011, is a bioelectronic medicine company that develops and commercializes innovative therapies for both acute and chronic inflammatory conditions. The company is headquartered in Woodland Hills, California.
Endonovo Therapeutics is focused on the development and commercialization of non-invasive bioelectronic therapies, which utilize safe electromagnetic fields to stimulate the body's natural healing processes. The company's proprietary technologies aim to address various medical conditions including pain management, tissue regeneration, and inflammation.
The flagship product of Endonovo Therapeutics is called SofPulse, which is a non-invasive device designed to stimulate the body's natural healing response by reducing inflammation and promoting tissue regeneration. SofPulse is based on pulsed electromagnetic field (PEMF) technology and is used in the post-operative care setting to accelerate wound healing and reduce pain.
SofPulse delivers low-frequency electromagnetic fields to the body, which have been shown to enhance the body's cellular communication system and promote healing at the cellular level. The device is currently being used in hospitals and surgical centers across the United States, showing positive results in reducing pain, edema, and opioid use in post-operative patients.
In addition to SofPulse, Endonovo Therapeutics is also developing other bioelectronic therapies for various medical conditions. These include Cytotronics, a platform technology designed to treat a range of diseases and disorders by modulating the body's electrical signaling system, and Immunotronics, which aims to stimulate the immune system and enhance its response to infections and diseases.
The company's development pipeline also includes Exosomes, which are naturally occurring extracellular vesicles that play a crucial role in cell-to-cell communication and have shown potential in regenerative medicine. Endonovo Therapeutics is exploring the therapeutic applications of exosomes in wound healing, tissue repair, and other medical conditions.
Endonovo Therapeutics operates in collaboration with leading academic institutions, research organizations, and medical centers to advance its technologies. The company's research and development efforts focus on conducting pre-clinical and clinical trials to demonstrate the safety and efficacy of its bioelectronic therapies.
Overall, Endonovo Therapeutics Inc is a bioelectronic medicine company that is dedicated to developing and commercializing innovative therapies for inflammatory conditions. The company's flagship product, SofPulse, has demonstrated positive results in accelerating wound healing and reducing pain in post-operative patients. With a robust pipeline of bioelectronic therapies, Endonovo Therapeutics is poised to make a significant impact in the field of regenerative medicine.
Endonovo Therapeutics is focused on the development and commercialization of non-invasive bioelectronic therapies, which utilize safe electromagnetic fields to stimulate the body's natural healing processes. The company's proprietary technologies aim to address various medical conditions including pain management, tissue regeneration, and inflammation.
The flagship product of Endonovo Therapeutics is called SofPulse, which is a non-invasive device designed to stimulate the body's natural healing response by reducing inflammation and promoting tissue regeneration. SofPulse is based on pulsed electromagnetic field (PEMF) technology and is used in the post-operative care setting to accelerate wound healing and reduce pain.
SofPulse delivers low-frequency electromagnetic fields to the body, which have been shown to enhance the body's cellular communication system and promote healing at the cellular level. The device is currently being used in hospitals and surgical centers across the United States, showing positive results in reducing pain, edema, and opioid use in post-operative patients.
In addition to SofPulse, Endonovo Therapeutics is also developing other bioelectronic therapies for various medical conditions. These include Cytotronics, a platform technology designed to treat a range of diseases and disorders by modulating the body's electrical signaling system, and Immunotronics, which aims to stimulate the immune system and enhance its response to infections and diseases.
The company's development pipeline also includes Exosomes, which are naturally occurring extracellular vesicles that play a crucial role in cell-to-cell communication and have shown potential in regenerative medicine. Endonovo Therapeutics is exploring the therapeutic applications of exosomes in wound healing, tissue repair, and other medical conditions.
Endonovo Therapeutics operates in collaboration with leading academic institutions, research organizations, and medical centers to advance its technologies. The company's research and development efforts focus on conducting pre-clinical and clinical trials to demonstrate the safety and efficacy of its bioelectronic therapies.
Overall, Endonovo Therapeutics Inc is a bioelectronic medicine company that is dedicated to developing and commercializing innovative therapies for inflammatory conditions. The company's flagship product, SofPulse, has demonstrated positive results in accelerating wound healing and reducing pain in post-operative patients. With a robust pipeline of bioelectronic therapies, Endonovo Therapeutics is poised to make a significant impact in the field of regenerative medicine.
Endonovo Therapeutics Inc. is a biotechnology company that primarily focuses on researching and developing innovative therapies for various medical conditions through the utilization of its proprietary platforms. The companys segments can be broadly categorized into its therapeutic product lines, technologies, and research collaborations, among other areas.
Product Segments
1. Therapeutic Devices:
- Endonovo has developed non-invasive electroceutical devices designed to improve patient health by modulating inflammatory responses and promoting tissue healing. These devices typically rely on advanced electrical stimulation methods to achieve these outcomes.
- The most notable product in this line is the “SENS SYSTEM”, which is designed for various indications, such as pain management, wound healing, and other conditions that could benefit from anti-inflammatory effects.
2. Drug Development:
- The company works on the development of novel pharmaceutical compounds, mostly focusing on anti-inflammatory and neuroprotective treatments. These drug candidates are typically geared towards conditions such as chronic pain, neurological disorders, and others.
- There are exploratory studies and clinical trials in progress that aim to establish the efficacy of these drug therapies, often in conjunction with their electroceutical technologies.
3. Research and Development:
- Endonovo is engaged in extensive R&D in both therapeutic device and pharmaceutical sectors. This includes preclinical and clinical studies to explore the mechanisms of action, safety, and efficacy of their products.
- The R&D segment often includes partnerships with academic institutions and other research entities to expedite innovation and development processes.
Services Offered
1. Clinical Trials:
- Endonovo Therapeutics conducts clinical trials to evaluate the safety and efficacy of its products. These trials typically involve multiple phases, ranging from small-scale Phase I safety studies to larger Phase III efficacy trials.
2. Collaborative Research:
- The company often engages in collaborative research agreements to leverage external expertise and resources in specific areas related to their therapeutic focus. This allows them to access cutting-edge research, technology, and methodologies.
3. Regulatory Affairs Consulting:
- As part of the development of its products, Endonovo must navigate the complex landscape of regulations associated with medical devices and pharmaceuticals. The company may provide consulting services in regulatory affairs, assisting in the preparation of IDE (Investigational Device Exemption), NDA (New Drug Application), and other submissions required by regulatory bodies such as the FDA.
4. Education and Training:
- Endonovo may offer educational resources and training programs for healthcare providers and practitioners to effectively use their devices and therapies. This ensures that users are properly informed about best practices and protocols.
5. Patient Support Programs:
- To enhance patient engagement and adherence, Endonovo might implement patient support programs that provide education, resources, and assistance to individuals using their therapeutic devices and drugs.
Future Directions
Endonovo Therapeutics is likely to pursue new indications for its existing products, expand its pipeline through novel therapeutic avenues, and strengthen its market position by establishing strategic partnerships. By staying at the forefront of biotechnology and utilizing their innovative technologies, Endonovo aims to address unmet medical needs in various therapeutic areas.
This comprehensive framework highlights the diverse segments, products, and services that Endonovo Therapeutics Inc. offers, reflecting their commitment to advancing healthcare through technological innovation.
Product Segments
1. Therapeutic Devices:
- Endonovo has developed non-invasive electroceutical devices designed to improve patient health by modulating inflammatory responses and promoting tissue healing. These devices typically rely on advanced electrical stimulation methods to achieve these outcomes.
- The most notable product in this line is the “SENS SYSTEM”, which is designed for various indications, such as pain management, wound healing, and other conditions that could benefit from anti-inflammatory effects.
2. Drug Development:
- The company works on the development of novel pharmaceutical compounds, mostly focusing on anti-inflammatory and neuroprotective treatments. These drug candidates are typically geared towards conditions such as chronic pain, neurological disorders, and others.
- There are exploratory studies and clinical trials in progress that aim to establish the efficacy of these drug therapies, often in conjunction with their electroceutical technologies.
3. Research and Development:
- Endonovo is engaged in extensive R&D in both therapeutic device and pharmaceutical sectors. This includes preclinical and clinical studies to explore the mechanisms of action, safety, and efficacy of their products.
- The R&D segment often includes partnerships with academic institutions and other research entities to expedite innovation and development processes.
Services Offered
1. Clinical Trials:
- Endonovo Therapeutics conducts clinical trials to evaluate the safety and efficacy of its products. These trials typically involve multiple phases, ranging from small-scale Phase I safety studies to larger Phase III efficacy trials.
2. Collaborative Research:
- The company often engages in collaborative research agreements to leverage external expertise and resources in specific areas related to their therapeutic focus. This allows them to access cutting-edge research, technology, and methodologies.
3. Regulatory Affairs Consulting:
- As part of the development of its products, Endonovo must navigate the complex landscape of regulations associated with medical devices and pharmaceuticals. The company may provide consulting services in regulatory affairs, assisting in the preparation of IDE (Investigational Device Exemption), NDA (New Drug Application), and other submissions required by regulatory bodies such as the FDA.
4. Education and Training:
- Endonovo may offer educational resources and training programs for healthcare providers and practitioners to effectively use their devices and therapies. This ensures that users are properly informed about best practices and protocols.
5. Patient Support Programs:
- To enhance patient engagement and adherence, Endonovo might implement patient support programs that provide education, resources, and assistance to individuals using their therapeutic devices and drugs.
Future Directions
Endonovo Therapeutics is likely to pursue new indications for its existing products, expand its pipeline through novel therapeutic avenues, and strengthen its market position by establishing strategic partnerships. By staying at the forefront of biotechnology and utilizing their innovative technologies, Endonovo aims to address unmet medical needs in various therapeutic areas.
This comprehensive framework highlights the diverse segments, products, and services that Endonovo Therapeutics Inc. offers, reflecting their commitment to advancing healthcare through technological innovation.